Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 526 - 550 of 847 in total
Investigational
Matched Iupac: … 3-[3-(6-carbamimidamido-1-oxo-2,3-dihydro-1H-isoindol-2-yl)propanamido]-3-(pyridin-3-yl)propanoic acid …
Investigational
Investigational
An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines. Additionally, genistein has antihelmintic activity. It has been...
Investigational
Investigational
NNC-55-0396 is a T-type Ca(2+) channel inhibitor.
Investigational
Investigational
N-oleoyldopamine (OLDA) is an amide of dopamine and oleic acid.
Investigational
Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.
Investigational
Matched Iupac: … 2-[4-({[(2R)-3,4-dihydro-2H-1-benzopyran-2-yl]methyl}amino)butyl]-2,3-dihydro-1lambda6,2-benzothiazole …
Caricotamide is under investigation in clinical trial NCT00746590 (Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma).
Investigational
Investigational
Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.
Investigational
Withdrawn
Urolithin A is a metabolite of ellagic acid. It has been demonstrated to stimulate mitophagy and improve muscle health in old animals and in preclinical models of aging.
Investigational
Bombesin is under investigation in clinical trial NCT01205321 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers).
Investigational
A selective inhibitor of dopamine uptake.
Investigational
Etamicastat is under investigation in clinical trial NCT02840565 (Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453).
Investigational
Matched Iupac: … 5-(2-aminoethyl)-1-[(3R)-6,8-difluoro-3,4-dihydro-2H-1-benzopyran-3-yl]-2,3-dihydro-1H-imidazole-2-thione …
Melarsomine is a trypanocidal agent marketed by Merial under the trade name Immiticide. It is the only FDA-approved treatment for adult heartworm infection in dogs, however, is is not approved for use in dogs with late-stage infection.
Experimental
Vet approved
Mocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others.
Investigational
Investigational
Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.
Investigational
DU125530 is under investigation in clinical trial NCT01119430 (Fluoxetine Versus Fluoxetine Plus DU125530 in Major Depressive Disorder).
Investigational
Matched Iupac: … 2-{4-[4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl}-2,3-dihydro-1lambda6,2-benzothiazole …
Dordaviprone (ONC-201) is under investigation in clinical trial NCT03394027 (ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma).
Investigational
Derazantinib is under investigation in clinical trial NCT03230318 (Derazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma).
Investigational
Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
Investigational
Displaying drugs 526 - 550 of 847 in total